-28%

est. 2Y upside i

Healthcare

Rank

#2902

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Medium

Guardant Health's equity offers a negative expected 2-year return of -27.8% due to a rich entry multiple of 19x revenue versus public peers at 5-8x, and the need for dilution.

Last updated: July 19, 2026

Bull (30%)+6%

Exit multiple holds at 15x due to Shield screening adoption and FDA label expansions. Projected revenue $2.08B yields exit value ~$31.2B, net 36.2% upside before 15% dilution.

Base (45%)-45%

Multiple compresses to 7x in line with public peers as growth slows. Exit value ~$14.6B, implying -29.5% upside before 15% dilution.

Bear (25%)-75%

Multiple falls to 4x under competitive and regulatory pressures. Exit value ~$8.3B, resulting in -59.7% upside before 15% dilution.

Est. time to liquidity~2.0 years

Preference Stack Risk

low

Funding Intensity

3%

Total funding of $557M represents only 2.7% of current valuation, so preferred liquidation preference is minimal.

Dilution Risk

moderate

With negative earnings and high cash burn, a capital raise within 24 months is likely, diluting common by 15-25%.

Secondary Liquidity

moderate

Secondary market exists per valuation source, but liquidity for individual shareholders may be limited and price-dependent.

View all 7 open roles at Guardanthealth →

Last updated: July 3, 2026

Questions to Ask at the Interview

Strategic questions based on Guardanthealth's data — designed to show you've done your homework.

  • 1

    “How does Guardant's Shield test differentiate from Exact Sciences' Cologuard, and what is the addressable market for blood-based colorectal cancer screening?”

  • 2

    “What is the company's path to profitability given 66% gross margins and 48% revenue growth?”

  • 3

    “How would you evaluate the dilution risk from a potential capital raise over the next 24 months?”

Community

Valuation Sentiment

Our model estimates -28% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.